Aggressive B-Cell Non-Hodgkin Lymphoma — Trials

Aggressive B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

400 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 115
Recruiting: 56
Ph III recruiting: 1
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (72)

clinicaltrialsPublishedShowing 1–50 of 88 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03015896	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	completed	Phase 1 / Phase 2	36	David Bond, MDOTHER	1	Sep 23, 2026	clinicaltrials
NCT04205409	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	completed	Phase 2	20	University of WashingtonOTHER	1	Jun 26, 2026	clinicaltrials